Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab), Panzem NCD, Panzem® NCD
Panzem NCD, Avastin · 4 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Panzem NCD | DRUG | 2000 mg q8h, continuous dosing in 28 day cycles |
| Temozolomide | DRUG | Fixed dose |
| Panzem® NCD | DRUG | NCD suspension, 1500 mg TID daily for 6 week cycles |
| Sunitinib Malate | DRUG | Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle |
| Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab) | DRUG | Panzem NCD 1,000 mg, four times daily for 28 consecutive days bevacizumab 5 mg/kg intravenous bolus on Day 1 and Day 15 |
Inclusion Criteria: 1. A histologically confirmed diagnosis of a recurrent/progressive primary WHO grade IV malignant glioma (glioblastoma multiforme or gliosarcoma). Patients with recurrent disease whose diagnostic pathology confirmed WHO grade IV malignant glioma (glioblastoma multiforme or glios...
Panzem NCD is an investigational small molecule being studied for the treatment of prostate cancer, recurrent glioblastoma multiforme, and metastatic renal cell carcinoma. It is in Phase 2 clinical development and has not been approved by the FDA.
Panzem NCD is being developed by CASI Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker CASI. The company is conducting clinical trials to evaluate the drug's safety and efficacy in oncology indications.
Panzem NCD is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. Clinical trials for the drug have been completed, and it is not currently in active trials.
Panzem NCD has been studied in three completed Phase 2 trials. NCT00394810 evaluated it in hormone-refractory prostate cancer with 21 patients. NCT00444314 tested it alone and with sunitinib in metastatic renal cell carcinoma with 82 patients. NCT00481455 studied it with temozolomide in recurrent glioblastoma multiforme with 15 patients.
Panzem NCD is a specific formulation of Panzem, known as Nanocrystal Colloidal Dispersion (NCD). This formulation is being studied in clinical trials for various cancers. The drug is also referred to by its brand name Panzem NCD in trial documentation.